Mel Hayes

Mel joined Fulcrum in September 2021 as Chief Commercial Officer and was subsequently appointed to the role of Chief Operating Officer in June 2022. Mel was appointed to Executive Vice President, Patient Experience, in October 2023. In this role Mel is responsible for developing an external facing integrated enterprise model that leverages the intersection of Patient Affairs, Advocacy, Access, Policy, and Communication to support the pipeline in both SCD and FSHD. Mel brings more than 30 years of experience in asset development and management of commercialization strategies in a range of therapeutic areas including many rare, specialty and primary care diseases. Prior to Fulcrum, Mel served as Global Head Commercial, Vice President, Rare Blood Disorders at Sanofi-Genzyme, where he led the commercial organization for hemophilia and complement assets. His previous roles also include U.S. Vice President, Hemophilia and Global Head, Hematology Rare Blood Disorders at Bioverativ (acquired by Sanofi-Genzyme) and Global Vice President, Head of Global Marketing and Launch Excellence at Shire and Global Vice President, Hemophilia at Baxalta (acquired by Shire). He also spent 10 years at Bayer and nine years at Bristol Myers Squibb in progressive leadership roles where he was responsible for launching products in diabetes, cardiovascular disease, neurology, rheumatology, multiple sclerosis, and Parkinson’s disease globally.

Mel earned dual bachelor’s degrees in business and communications from Southern Methodist University and received his MBA from Columbia University.